Contemporary pressures — from online pharmacies and novel psychoactive substances to antimicrobial resistance and supply-chain fragility — make coordinated international action more important than ever.
Core frameworks and institutions
International conventions on narcotic drugs and psychotropic substances provide the legal backbone for scheduling and cross-border control.
Multilateral organizations and expert networks support national regulators by issuing guidance on safety, quality and efficacy standards. Harmonization initiatives promote common technical requirements for drug development and approval processes, reducing duplication and speeding patient access to important therapies.
Key regulatory challenges
– Proliferation of online and cross-border sales: Unregulated online pharmacies and telemedicine services can enable unsafe prescribing and allow counterfeit or substandard products to cross borders quickly. Enforcement lags behind technology, creating gaps in patient protection.
– Novel psychoactive substances (NPS): Rapid emergence of new chemical entities designed to evade scheduling makes traditional control systems reactive rather than preventive.
Early-warning systems and flexible scheduling approaches are essential.
– Counterfeit and substandard medicines: Weak supply-chain visibility and limited laboratory capacity in some regions permit low-quality or falsified products to reach patients, undermining treatment outcomes and trust.
– Antimicrobial resistance (AMR): Overuse and inappropriate access to antibiotics is a global threat. Regulatory action must align with stewardship programs and diagnostics to preserve effective therapies.
– Regulatory capacity and convergence: Many low- and middle-income countries face resource constraints that slow approvals, inspections and post-market surveillance. At the same time, global clinical development and manufacturing trends call for more regulatory convergence and mutual reliance.
Practical approaches that work
– Strengthen information-sharing and rapid alert networks so safety signals, falsified-product alerts and intelligence on illicit supply routes move quickly between agencies and customs authorities.
– Adopt regulatory reliance and mutual recognition for inspections and approvals where confidence in partner regulators exists. This accelerates patient access without duplicating effort.
– Implement serialization and track-and-trace systems across the supply chain to raise the cost and complexity of diversion and counterfeiting. Pilot projects combining serialization data with risk-based analytics have shown promise in preventing illicit entry points.
– Expand pharmacovigilance and product quality monitoring using risk-based sampling, sentinel sites and crowd-sourced reporting while safeguarding data privacy.
– Modernize controls for online pharmacies and telemedicine by requiring verified accreditation, credential checks for prescribers and stronger online marketplace responsibilities.
– Align drug scheduling policy with public health objectives. Flexible scheduling mechanisms and emergency-use pathways help manage new psychoactive risks and ensure continuity of care during crises.
– Integrate antimicrobial stewardship into regulatory approvals and reimbursement policies, linking access to diagnostics and appropriate use programs.
Capacity building and international cooperation
Investing in regulatory science, laboratory networks and workforce training strengthens the entire system.
Donor agencies, regional regulatory networks and public–private partnerships can accelerate capability building. Cross-border cooperation—through joint inspections, shared laboratory resources and technical assistance—reduces disparities that scammers exploit.
The path forward blends enforcement, public-health priorities and technological innovation. Regulators that prioritize cooperation, transparency and adaptive policy frameworks can better protect patients, support legitimate access to medicines and reduce the harms associated with illicit and substandard drug markets.